The Canadian cannabis stocks continue to trade near the yearly lows and the Cannabis 2.0 rollout can’t start soon enough. Unfortunately, Canopy Growth just...
Near the end of November 2019 Aurora Cannabis (ACB) found it would no longer be able to sell medical cannabis to the German market until the company obtains a...
Despite the promising launch of Cannabis 2.0 products next week, a stock like HEXO (HEXO) still trades at yearly lows down 75% from the highs. The Canadian...
It’s safe to say things aren’t so rosy for New Age Beverages (NBEV) stock. Shares have plummeted around 65% year-to-date in line with the trajectory of the...
Public opinion on cannabis is changing quickly, growing ever more lenient. In a short span, less than a lifetime, we’ve seen a series of decriminalization...
The Canadian cannabis market is heading into a major catalyst with the unleashing of Cannabis 2.0 products in mid-December. Canopy Growth (CGC) remains an...
The major benefit to U.S. cannabis stocks are the big catalysts ahead for the related companies due to legal changes providing more access to markets. Outside...
A big thesis of the Canadian cannabis LPs investment story was global expansion. The news last week of Aurora Cannabis (ACB) being blocked from Germany sales...
The FDA recently sent 15 warning letters to privately held companies concerning violations surrounding the inclusion of CBD in human and animal drugs, as well...
While the cannabis sector faces capital concerns, Aphria (APHA) was just able to secure a reasonably priced financing. The move possibly changes the equation...
